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Osteoclastic bone resorption is a prominent feature of
periodontal disease. Bone resorption via osteoclasts
and bone formation via osteoblasts are coupled, and
their dysregulation is associated with numerous dis-
eases of the skeletal system. Recent developments in
the area of mediators of osteoclastic differentiation
have expanded our knowledge of the process of
resorption and set the stage for new diagnostic and
therapeutic modalities to treat situations of localized
bone loss as in periodontal disease. This review
describes the current state of knowledge of osteoclast
differentiation and activity, mediators, and biochem-
ical markers of bone resorption and their use and
potential use in clinical periodontics. Finally, thera-
peutic strategies based on knowledge gained in the
treatment of metabolic bone diseases and in peri-
odontal clinical trials are discussed, and the potential
for future strategies is proposed relative to their bio-
logic basis. The intent is to update the field of peri-
odontics on the current state of pathophysiology of the
osteoclastic lesion and outline diagnostic and thera-
peutic strategies with a rational basis in the under-
lying biology. J Periodontol 2002;73:1377-1391.
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Destruction of the osseous support of the dentition is
a hallmark of periodontal diseases. This localized
bone resorptive process has been the target of ther-
apeutic intervention and preventive strategies; hence,
understanding the underlying mechanisms is critical
for the effective treatment of periodontitis. Factors
that perturb either bone formation or bone resorp-
tion will alter the overall quality and quantity of bone.
Bone formation and resorption are coupled, and in a
healthy adult, are in a state of balance. During devel-
opment, bone formation is greater than bone resorp-
tion, with a resultant increase in bone mass. Optimal
periodontal regenerative procedures recapitulate this
process. Inhibiting the mediators of osteoclast acti-
vation can also result in an increase in bone mass.
Consequently, it is important to consider the mech-
anisms of action of factors that stimulate resorption,
their clinical identification, and their control. Fur-
thermore, agents that are currently in use to diag-
nose and treat conditions of systemic bone loss, such
as osteoporosis, may prove valuable to also target the
periodontium. This review will address basic princi-
ples and current concepts in bone remodeling, medi-
ators of bone resorption and their clinical relevance,
and diagnostic and therapeutic potentials to treat
bone resorption specifically associated with peri-
odontitis.
BONE REMODELING: BASIC PRINCIPLES AND
CURRENT CONCEPTS
It has long been accepted that bone formation and
bone resorption are processes that are “coupled,”
although periodically there is evidence suggesting
they can act independently.1 This coupling process
entails that osteoclasts resorb an area of bone, and
osteoblasts are signaled to come in and replace bone
(Fig. 1). The resorptive phase occurs over a 3- to 4-
week period, whereas the formative phase occurs
over a 3- to 4-month period for one unit called a
basic multicellular unit (BMU) that includes
osteoblasts and osteoclasts.2 Between the resorptive
and formation phases is a period termed the rever-
sal phase. During the reversal phase, cells that appear
morphologically inactive line the resorption lacunae.
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It is estimated that the adult skeleton contains more
than 1 million BMUs at any time, with nearly 5-fold
more occurring in trabecular bone versus cortical
bone.3 The net result is an exchange of 10% of the
skeleton over a 1-year period. It follows that trabec-
ular bone is more susceptible to conditions of
turnover. This is an important concept when consid-
ering the impact of systemic skeletal diseases on
bone of the oral cavity, which has a higher cortical-
to-trabecular bone ratio than vertebrae, for example.
Osteoblasts, the cells responsible for bone forma-
tion in the BMU, are derived from mesenchymal pre-
cursor cells and go through a well-defined pattern of
differentiation.4 Current data suggest that osteoblasts
arise from progenitors of the marrow and also peri-
cytes, mesenchymal cells adherent to the endothe-
lial layer of vessels.5,6 Precursor cells differentiate
into preosteoblastic cells through the action of bone
morphogenetic proteins (BMPs). BMPs are the only
factors that have been found capable of initiating
osteoblastogenesis from uncommitted progenitors.7
Other factors such as transforming growth factor-β,
platelet-derived growth factor (PDGF), insulin-like
growth factors (IGFs), and fibroblast growth factors
(FGFs) promote osteoblast proliferation and hence
support their use in periodontal regenerative strate-
gies.8 Once the osteoblast matures into an active
matrix-producing cell, it expresses many of the phe-
notypic characteristics that are used to identify it such
as osteocalcin, the PTH/PTHrP receptor, and bone
sialoprotein.4 The lifespan of an osteoblast has been
estimated to be 3 months. The osteoblast subse-
quently becomes an osteocyte entrapped in the bone
matrix, dies via apoptosis, or




shown to stimulate apoptosis of
osteoblastic cells.9
Osteoclasts are cells derived
from the hematopoietic lineage
and gain access to sites of
resorption via the blood supply.
They are identified by their
expression of an osteoclastic
enzyme, tartrate-resistant acid
phosphatase (TRAP) and by
typically having 3 or more
nuclei per cell. Other charac-
teristic morphologic features of
osteoclasts are the ruffled mem-
brane and clear zone that assure the resorptive
process remains localized beneath the osteoclast, and
the proton pump that regulates hydrogen ion con-
centration and thus pH in the bone resorptive
microenvironment. It has long been known that the
development of osteoclasts depends on the presence
of accessory cells, most notably marrow stromal cells
or osteoblasts.10 Interestingly, more recently, lym-
phocytes have also been found to support osteoclast
generation.11 There are 2 molecules considered essen-
tial and sufficient to support osteoclastogenesis:
macrophage colony-stimulating factor (M-CSF, or
CSF-1) and receptor activator of nuclear factor kappa
B ligand (RANKL) (Fig. 2). M-CSF is a secreted fac-
tor, but the cell surface form of RANKL requires a
juxtacrine (cell to cell) interaction. Other transcrip-
tion factors and enzymes associated with osteoclast
development include PU.1, c-src, c-fms, carbonic
anhydrase II, matrix metalloproteinase 9, and cathep-
sin K.10 Many of these have been the focus of ther-
apeutic strategies to target systemic bone loss.12
Recently, a new member of the leukocyte receptor
complex (LRC)-encoded family was identified and
found to be expressed exclusively in osteoclasts.13
Named OSCAR for osteoclast-associated receptor, it
is expressed exclusively in osteoclasts late in differ-
entiation and, hence, is thought to play a regulatory
role in the differentiation of osteoclasts via interac-
tion with a ligand on osteoblasts/stromal cells.
The process of bone resorption is initiated with a
resorptive stimulus (Table 1).12,14 These stimulators
typically affect bone resorption through the activation
of M-CSF or RANKL,11 although in pathologic states,
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Figure 1.
The bone remodeling cycle. Preosteoclasts are recruited to sites of resorption, induced to differentiate
into active osteoclasts, and form resorption pits.After their period of active resorption, they are
replaced by transient mononuclear cells.Through the process of coupling, preosteoblasts are
recruited, differentiate into active matrix secreting cells, and form bone. Some osteoblasts become
entrapped in the matrix and become osteocytes.
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mediators such as tumor necrosis factor-α (TNF-α)
and interleukin (IL)-1 may act independently of
RANKL.15 A key early event in the bone resorptive
process is the attachment of the osteoclast to the
bone matrix.14 This matrix attachment is mediated by
integrins, primarily αVβ3, and results in the intimate
contact of the osteoclast with the matrix to be
resorbed and the formation of the
sealing zone that enables the osteo-
clast to isolate a microenvironment
beneath it to facilitate resorption.16
Once activated, the osteoclast cre-
ates the acidic environment beneath
it via H+-ATPase activity of the ruf-
fled membrane proton pump, which
is responsible for dissolving the
mineral component of the matrix
(Fig. 3). Secretion of HCl into the
resorptive microenvironment results
in a pH of 4.5 necessary for mobi-
lization of the bone mineral.10 The
organic component is degraded by
matrix metalloproteinases (MMPs)
and cathepsin K, a lysosomal cys-
teine protease, in addition to several
other cathepsins that may be in-
volved.16 Products of the degrada-
tion process are then endocytosed
by the osteoclast and transported
to the opposite membrane of the cell and released.
Osteoclasts likely undergo repeated cycles of resorp-
tion in an area and then move to a new site to evoke
another cycle of resorption or alternatively undergo
apoptosis and, hence, cease resorption. Since the
lifespan of an osteoclast is, on average, about 2
weeks, it follows that these cells are intensely active
during their tenure, and agents that alter osteoclast
apoptosis can dramatically change the bone resorp-
tive process.2
Mediators of Bone Resorption
Numerous cytokines have been identified as media-
tors of bone resorption, and it is not surprising that
these are also found as putative mediators in peri-
odontal disease (Table 1). The classic studies, per-
formed by Horton et al., identified an osteoclast acti-
vating factor (OAF) that was produced in response
to periodontal plaque bacteria.17 This OAF was later
found to be IL-1, one of the most potent bone resorp-
tive agents. IL-1 is secreted in 2 molecular forms,
IL-1α and IL-1β, by a variety of cells including
macrophages, B cells, neutrophils, fibroblasts, and
epithelial cells, and is involved in the proinflammatory
process, matrix degradation, and wound healing.18
Due to its strong relationship with bone resorption, this
cytokine has received considerable attention as an
inflammatory cytokine with potential as a marker for
active bone loss. Interleukin-1 has also received spe-
cial attention because a high percentage of the pop-
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Figure 2.
Osteoclast differentiation pathway. Cells of the hematopoietic lineage are induced to become
osteoclasts through the action of M-CSF and RANKL. RANKL is a cell surface protein on
stromal cells (osteoblasts and lymphocytes also have RANKL) that is critical for differentiation
and activation of osteoclasts. OPG can effectively block the action of RANKL by acting as a
decoy receptor.
Table 1.
Mediators of Bone Resorption
Stimulators Inhibitors
Interleukin-1 (IL-1) Interferon gamma (IFN-γ)
Interleukin-6 (IL-6) Osteoprotegerin (OPG)
Tumor necrosis factor (TNF) Estrogens
Parathyroid hormone (PTH) Androgens
PTH-related protein (PTHrP) Calcitonin (CT)
Prostaglandin E2 (PGE2) Cyclosporin
Macrophage colony-stimulating 
factor (M-CSF)
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ulation carries a genetic polymorphism in the IL-1
gene that results in increased levels upon bacterial
challenge.19 These increased levels have been asso-
ciated with increased periodontal disease severity in
a population of patients. Interleukin-6 is also an
inflammatory cytokine with similar activity to stimu-
late bone resorption and has been implicated to have
a role in several disease states associated with accel-
erated bone remodeling.2 Prostaglandin E2 (PGE2)
and parathyroid hormone-related protein (PTHrP)
stimulate bone resorption and have been reported to
act indirectly through their activation of RANKL on
cells of the osteoblast lineage,20,21 whereas TNF-α
and IL-1α are thought to act directly on cells of the
osteoclast lineage to stimulate bone resorption.15 Sys-
temically, vitamin D3 and parathyroid hormone (PTH)
are considered the 2 main mediators of bone resorp-
tion; however, recent interest has centered on the
anabolic actions of PTH, as it is a promising thera-
peutic agent for the treatment of osteoporosis.22
Recently, a family of osteoclast mediators involved
in the TNF signaling pathway was identified that may
have a striking impact on the treatment of clinical
disorders such as periodontal disease. As indicated
above, RANKL (also known as osteoprotegerin-
ligand, OPG-L, or TRANCE) is a cell surface protein
present on osteoblastic cells and is responsible for
osteoclast differentiation and bone resorption.11,23
RANKL interacts with its receptor,
RANK, on hematopoietic cells, an
interaction thought to be essential for
osteoclast activation (Fig. 2). In the
absence of RANKL, osteoclastic
resorption is reduced, and increases in
bone mass occur.24
There are relatively fewer inhibitors
of bone resorption than stimulators of
resorption (Table 1). A soluble factor,
osteoprotegerin (OPG), binds to
RANKL and inhibits the differentiation
of osteoclasts.25 Hence, injection of
OPG in animals and humans potently
inhibits bone resorption, and its use
results in an increase in bone mass.
OPG is being explored in human clin-
ical trials for the treatment of osteo-
porosis, metastatic bone disease, and
also in animal models of rheumatoid
arthritis and periodontal disease.11,26
Interferon γ is a cytokine produced by
activated T lymphocytes that inhibits
bone resorption by inhibiting the dif-
ferentiation of committed precursors to mature cells.27
Systemically, calcitonin is a potent inhibitor of bone
resorption but, in pharmacologic use, has limited
application since patients become refractory to its
inhibitory action.28 Estrogen is another systemic hor-
mone that inhibits bone resorption as evidenced by the
increase in osteoporosis that ensues with estrogen
deficiency after menopause. Although its mechanisms
of action are not entirely clear, it is thought to pro-
mote the programmed cell death of osteoclasts and
hence reduce their period of activity.12,28 Pharmaco-
logic agents that inhibit bone resorption include
cyclosporin, at least in part associated with its anti-
inflammatory properties, and bisphosphonates, which
also stimulate osteoclast apoptosis.29,30
Systemic Biochemical Markers of Bone Resorption
Considerable progress has been made in the identi-
fication and development of systemic biochemical
markers of bone resorption; however, their utility is
still not widely accepted. The 5 most intensively
investigated factors are hydroxyproline; hydroxyly-
sine glycosides; pyridinium cross-links and related
collagen fragments (telopeptides); tartrate-resistant
acid phosphatase (TRAP); and bone sialoprotein
(BSP).31
The bone matrix is composed of 70% mineral and
30% organic components, the greatest of which is
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Figure 3.
The resorption process. Osteoclasts adhere to the matrix via the sealing zone and the action
of integrins.This seal creates the subcellular microenvironment critical for the resorption
process.The proton pump in the ruffled border acidifies the microenvironment through
hydrogen ions, and proteases produced by the osteoclast are responsible for degradation of
the organic matrix. Breakdown products of collagen degradation are transported through the
cell to the external bone environment and can be detected in the circulation.
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type I collagen. Type I collagen comprises 90% of
the organic matrix of bone; hence, during bone
resorption, breakdown products of collagen are
released into the circulation and may be detected in
the serum and/or urine.
Hydroxyproline (OHPr) is an amino acid that
occurs mainly in fibrillar collagens and accounts for
13% to 14% of the total amino acid content.31
Because it occurs almost exclusively in collagen, its
urinary levels have long been considered to reflect
collagen turnover in bone and other tissues. Its draw-
backs include the findings that 10% of the OHPr found
in the urine represents new collagen synthesis and not
collagen breakdown, and that it is found in many col-
lagens which are not found in bone; therefore, its
detection may not be specific for bone. Hydroxyly-
sine is also unique to collagen, and its glycosylation
to galactosyl hydroxylysine (GH) is associated more
frequently with type I collagen of bone versus type I
collagen, for example, of skin.31 Hence, measure-
ments of GH are thought to reflect mainly breakdown
of bone collagen. Collagen pyridinium cross-links,
pyridinoline or hydroxylysylpyridinoline (PYD), and
deoxypyridinoline (DPD) are currently considered the
most promising markers of systemic bone resorp-
tion.31,32 PYD and DPD are derived from hydroxyly-
sine and lysine residues in the collagen molecule.
These cross-links function to covalently link colla-
gen molecules between 2 telopeptides and a triple
helical sequence and provide stability to the colla-
gen fibrils (Fig. 3). The main sites of collagen cross-
linking are the short non-helical peptides at both ends
of the collagen molecule (N- and C-terminal telopep-
tides). These telopeptides are linked via pyridinium
or pyrrole compounds to the helical portion of neigh-
boring collagen molecules and can be detected dur-
ing collagen breakdown. DPD is more concentrated
in bone than PYD, and both are absent from the col-
lagen in normal skin. During the bone resorptive
process, pyridinoline cross-links are released and can
be detected in the urine as free amino acid deriva-
tives and oligopeptide-bound fractions. Several
immunoassays utilizing antibodies against the free
amino acids or the peptides containing the cross-link
components (N- and C-terminal telopeptides) in the
serum or urine are being used to monitor systemic
therapy in osteoporosis.33
Tartrate-resistant acid phosphatase is an enzyme
that is generally specific to osteoclasts, although not
exclusively.14 Immunoassays have been developed
to measure TRAP in serum as a reflection of osteo-
clastic activity, but only limited clinical applications
are available.31 Another resorptive marker, bone sialo-
protein (BSP), is an extracellular matrix, glycosylated
non-collagenous protein found in high levels at areas
of active mineralization. Interestingly, although BSP
is expressed in highest levels by active osteoblasts,




Traditional periodontal diagnosis involves measures
of probing depth, gingival recession, and calculated
probing attachment level using a graduated peri-
odontal probe. These are indirect measures of bone
loss. A number of factors such as the presence of
inflammatory changes or long junctional epithelium
or the pressure applied to the probe can affect peri-
odontal probing, leading to inaccuracies in recording
the true pocket depth.34 The height of the alveolar
bone margin and the shape and form of its outline are
also examined with radiographs. Unfortunately, the
sensitivity of radiographs in detecting an early osseous
lesion is poor.35 Many months to years may be needed
to detect measurable changes in bone density, whereas
biochemical markers can detect changes in a short
time. More sophisticated techniques such as subtrac-
tion radiography and computer-assisted image analy-
sis have been used as research tools to detect small
changes in bone mass, but at present, these have not
found a place in routine clinical practice.36
Gingival crevicular fluid (GCF), an exudate that
can be harvested non-invasively from the gingival
sulcus or periodontal pocket, contains a rich array
of cellular and biochemical mediators that reflect the
metabolic status of periodontal tissues.37,38 As GCF
transverses the inflamed tissue, it carries molecules
involved in the destructive process, and therefore
offers great potential as a source for factors that may
be associated with osteoclastic activity with the poten-
tial of being detected in advance of irreversible bone
loss. Further, in contrast to biochemical markers iden-
tified in metabolic bone diseases as discussed above,
GCF has the benefit of being closely approximated
to the site of destruction and thus may provide more
information than markers in the serum or urine. Sev-
eral materials have been analyzed in crevicular fluid
including plasma proteins, enzymes with col-
lagenolytic activity, other microbial and host cell
enzymes, and inflammatory mediators in attempts to
identify factors to facilitate the diagnosis of active
periodontal disease.38,39 Furthermore, similarities in
components of GCF from implant sites versus natural
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teeth suggest that components reflecting tissue break-
down are likely derived from the alveolar bone, since
a periodontal ligament source is not present in implant
sites. For convenience, GCF products can be grouped
into 3 general categories: 1) inflammatory mediators
and products; 2) host-derived enzymes; and 3) extra-
cellular matrix components.
Inflammatory Mediators and Products
Cytokines. Cytokines, specifically interleukin-1α (IL-
1α), IL-1β, IL-6, and TNF-α have been found in GCF
in relation to the progression of periodontal destruc-
tion.40-42 IL-1 has been the focus of numerous stud-
ies because it has such potent bone resorbing activ-
ity and is an inflammatory mediator with an obvious
role in periodontal tissue destruction. Both the IL-1α
and IL-1β forms have been detected in gingival crevic-
ular fluid, and IL-1β concentrations increase signifi-
cantly during episodes of periodontal inflammation.40
In a cross-sectional study, levels of IL-1β were
increased at periodontitis sites compared to gingivi-
tis and healthy sites.43 IL-1β also has synergistic
activity with other potent bone resorbing molecules
such as TNF-α or lymphotoxin in stimulating bone
resorption.44 After periodontal therapy, IL-1β levels
decrease significantly.45 Alveolar bone loss in sites
of active periodontal disease is associated with
increased levels of IL-1β in GCF.46,47 Furthermore,
elevated levels of IL-1β and IL-6 are associated with
periodontal pathogens such as Eikenella corrodens
and Prevotella intermedia and continuous loss of
attachment and alveolar bone loss in active sites.
This suggests that these cytokines might predict and
be associated with progressive attachment loss.
There is preliminary evidence that GCF from sites
with progressing periodontitis contains elevated
amounts of IL-6.48,49 IL-6 appears to be elevated in
GCF and biopsy specimens from sites that do not
favorably respond to phase I therapy.49 Furthermore,
increased levels of bone resorbing cytokines in GCF
are related to low systemic levels of estrogen.50
Prostaglandin E2. Several cross-sectional studies
have shown that GCF from sites with periodontitis
contains significantly increased levels of PGE2 com-
pared to healthy sites and those with gingivitis.51-54
Offenbacher et al. indicated that the diagnostic poten-
tial of PGE2 increased 2- to 3-fold in inflammation and
5- to 6-fold during periods of active attachment loss
and bone resorption.51 A ligature-induced experi-
mental periodontitis study in animals indicated that
GCF levels of PGE2 are markedly elevated during the
development of attachment loss and bone resorp-
tion.52 Total amounts and concentrations of PGE2 are
significantly higher in periodontitis as compared to
healthy and gingivitis sites and are positively corre-
lated with probing depth and gingival index.53 Stud-
ies suggest that this marker has considerable poten-
tial as a diagnostic marker of active disease and is
predictive of future bone loss.51,52,54 Unfortunately,
the currently available test required to detect PGE2
in gingival crevicular fluid is complex and not easy
to perform as a chairside diagnostic test.
Host-Derived Enzymes
Alkaline phosphatase. Alkaline phosphatase (ALP)
plays a role in bone metabolism and has been used
as a marker of the osteoblast-differentiated cell phe-
notype.31 ALP is found in many cells of the peri-
odontium including osteoblasts, fibroblasts, and neu-
trophils. Some forms of the enzyme are also produced
by plaque bacteria.55 Alkaline phosphatase levels in
GCF are higher than in serum.56 In serum, the
enzyme is associated with systemic bone disease,
and its elevation in GCF could well reflect changes
of alveolar bone in localized areas. Increased levels
of alkaline phosphatase have been noted in experi-
mental gingivitis studies at periodontitis sites and
may serve as a predictor of future or current disease
activity.56-58 Cross-sectional data indicate that GCF
from sites with gingivitis or periodontitis has signifi-
cantly higher concentrations of ALP than healthy sites
and that it positively and significantly correlates with
probing depth, but not bone loss.56,59 GCF ALP is
also elevated in patients with progressing lesions.
However, with the current data regarding ALP levels
in GCF relative to periodontal destruction, it would
seem that its predictive value is low.
Collagenase and related metalloproteinases.
Matrix metalloproteinases, such as the collagenases
stromelysin and elastase, are found in the tissue or
inflammatory exudate in periodontal lesions. These
enzymes are attractive candidates as markers of peri-
odontal destruction since they can specifically cleave
and degrade collagen and connective tissue matrix
macromolecules. Several reports have revealed a
positive correlation between collagenase or related
metalloproteinases in GCF and the severity of peri-
odontal disease.60,61 Golub et al. recognized the diag-
nostic merit of collagenase, since they found the
enzyme more positively correlated with probing depth
than inflammation.62 In human periodontitis, GCF
collagenase activity has been shown to increase with
increasing severity of gingival inflammation and
increasing probing depth and alveolar bone loss.63,64
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Cross-sectional studies clearly indicate that GCF from
sites with adult or juvenile forms of periodontitis
exhibits significantly elevated collagenolytic activi-
ties compared to GCF from healthy or gingivitis
sites.64-66
Collagenase also has been considered as a diag-
nostic marker of periodontal bone destruction around
endosseous dental implants. Levels of collagenase,
gelatinase, and elastase around dental implants are
similar to natural teeth.67 Collagenase-2 and colla-
genase-3 in GCF have been associated with implant
sites with progressive bone loss and hence may reflect
peri-implant osteolysis.68 Future studies are needed
to assess disease activity around dental implants with
these markers, but the diagnostic sensitivity and
specificity values for active collagenase as a predic-
tor of attachment loss are still considered low.
Extracellular Matrix Components
Osteonectin and osteopontin. Osteonectin (ON, also
known as SPARC) is a non-collagenous calcium-bind-
ing protein associated with the extracellular matrix
of many tissues, especially bone, and is thought to
play a role in remodeling and repair.69 Osteonectin
has been reported to be elevated in GCF at sites with
severe periodontitis.70 However, ON is liberated from
many different cell types as a heat shock protein,
and studies have shown that heat, a major clinical
sign of inflammation, induces their synthesis. Thus,
ON in GCF may also relate to inflammation in gen-
eral and, therefore, it may discriminate poorly
between gingival inflammation and bone resorptive
disease. Osteopontin (OPN) is a highly glycosylated
extracellular matrix protein that is produced by
osteoblasts, osteoclasts, and macophages with
increased levels in active sites of bone metabolism.71
Recently, OPN levels were detected in GCF and found
to correlate with probing depth,72 suggesting that it
may be a predictor of periodontal attachment loss, but
this needs to be confirmed.
Osteocalcin (OCN). Osteocalcin is another extra-
cellular matrix protein that is associated with bone for-
mation.4 OCN has been identified in gingival crevic-
ular fluid and studied in relation to clinical parameters.
No detectable levels of OCN were found in crevicu-
lar fluid in a small group of patients with gingivitis,
while patients with untreated periodontitis had OCN
levels 200 to 500 times higher than in serum.73
Another cross-sectional study found OCN present in
higher levels in diseased sites versus healthy sites,
and mean concentrations in GCF were more than 10
times higher than normal serum levels and correlated
with clinical parameters such as gingival index, but
not probing depth.53 Giannobile et al. investigated
the relation of GCF osteocalcin levels to the pro-
gression of ligature-induced experimental periodon-
titis in beagle dogs and suggested that OCN levels in
GCF may serve as a predictor of bone turnover in
experimental periodontitis.74 However, in human stud-
ies, no difference in osteocalcin content has been
found between active and inactive sites.75,76
Cross-linked carboxyterminal telopeptide of type
I collagen (ICTP). There is a strong correlation
between ICTP levels and deoxypyridinoline levels
and clinical parameters of tissue destruction such
as radiographic bone level and probing depth.77,78
Significantly higher GCF ICTP concentrations were
found in patients with periodontitis versus healthy
patients, with GCF levels 100 times higher than
serum reference levels.77 Furthermore, periodontal
treatment reduces the GCF ICTP concentrations to
levels found in healthy subjects as early as 2 days
after treatment. In contrast, although deep peri-
odontal sites demonstrated higher ICTP levels in
humans, a single episode of non-surgical therapy
did not significantly reduce ICTP levels.79 Palys et al.
suggested a relationship between selected subgingi-
val pathogens and the C-telopeptide pyridinoline
cross-link, and concluded that under appropriate
conditions, certain subgingival species may stimu-
late a host response that can lead to cytokine
release, induction of osteoclast activity, and cleav-
age of pyridinoline cross-links in bone collagen.80 A
longitudinal study in ligature-induced experimental
periodontitis in beagle dogs reported that GCF ICTP
levels increased significantly 2 weeks following ini-
tiation of the disease.74 This increase preceded the
increase in bone-seeking radiopharmaceutical uptake
(BSRU) by 2 weeks and the radiographical evidence
of bone loss by 4 weeks. The authors concluded that
GCF ICTP related positively to indices of active alve-
olar bone loss in experimental periodontitis and may
serve as a marker for future alveolar bone loss. Still,
its use clinically will depend on the results of human
longitudinal studies.
Oringer et al. reported that GCF ICTP levels and
subgingival plaque composition were not significantly
different between implants and natural teeth and that
elevated ICTP levels were associated with disease
progression.81 Longitudinal studies are required to
determine whether elevated ICTP levels may predict
the development of peri-implant bone loss.
Glycosaminoglycans (GAGs). The sulcular fluid
appears to be rich in metabolic or degradative prod-
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ucts of the proteoglycans found in the various peri-
odontal tissues. Some site specificity for various gly-
cosaminoglycans in the periodontium has been noted;
the gingival connective tissue is rich in dermatan sul-
fate, while alveolar bone is rich in chondroitin sul-
fate.82 Sulfated glycosaminoglycans in GCF have
been associated with clinical situations where altered
metabolic activity of the alveolar bone is evident,
including early, advanced, and juvenile periodontitis,
but not chronic gingivitis, where bone loss is not pres-
ent.83,84 This suggests that the presence of raised
levels of sulfated GAGs in GCF reflect active destruc-
tion of periodontal tissue, likely alveolar bone. Fur-
ther, the high concentration of chondroitin sulfate in
crevicular fluid sampled from sites of active bone
resorption has been interpreted to indicate that this
GAG originates from the matrix of the alveolar bone.83
Levels of chondroitin sulfate are significantly higher
in diseased patients as compared to healthy pa-
tients.85 Giannobile et al. reported elevated GCF GAG
levels in increasing severity of disease and concluded
that GAG analysis in GCF may be used to detect
early preclinical changes in the periodontal tissues.86
High levels of chondroitin sulfate are also found in
non-inflamed sites undergoing orthodontic tooth
movement, which implies an association between
chondroitin sulfate in crevicular fluid and bone resorp-
tion.87
Two major glycosaminoglycan components, hyaluro-
nan and chondroitin-4-sulfate,
have been detected in peri-
implant sulcular fluid.88,89 High
levels of chondroitin-4-sulfate
have been found immediately
following exposure and occlusal
loading of implants.90 This sug-
gests that chondroitin-4-sulfate
in gingival crevicular fluid may
be a marker of bone break-
down, since there would not be
a contribution by the periodon-
tal ligament. The peri-implant
sulcular fluid GAG profile may
also be a useful method of mon-
itoring implants to detect adverse
tissue responses at an early
stage. Dot blot assays and
enzyme-linked immunosorbent
assay provide an accurate
assessment of the glycosamino-
glycan level with the simplicity
of a “chairside” application. The
potential for chondroitin sulfate to be a useful marker
of active bone resorption appears to be promising
but requires further detailed investigation.
PHARMACOLOGICAL STRATEGIES FOR
TREATING PERIODONTAL BONE LOSS
Pharmacologic strategies designed to treat peri-
odontal bone destruction generally either target the
bacteria in the lesion or the host response to the bac-
teria. Historically, most strategies have focused on
the bacteria, whereas pharmacologic strategies that
specifically inhibit the formation or activity of osteo-
clasts have been less intensively utilized. Still, many
of these osteoclastic pathway inhibitors have proved
valuable for treating systemic diseases associated
with bone loss such as osteoporosis and Paget’s dis-
ease.12 Targeting the host response via inhibition of
bone resorption may be accomplished by altering
the differentiation of osteoclasts, the specific com-
ponents necessary for the process of resorption, or
the duration of their activity via reducing their lifespan
(Fig. 4).
Anti-Inflammatory Agents
Agents that block cytokine production or activity are
the early strategies to inhibit bone resorption. His-
torically, non-steroidal anti-inflammatory agents
(NSAIDs) have provided promising results in slowing
periodontal destruction.91 Adverse reactions, how-
ever, have limited their widespread use.92 Studies of
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Figure 4.
Potential therapeutic strategies to treat bone resorption.Agents that block the differentiation or
activity of osteoclasts are potential therapeutic agents. OPG inhibits the differentiation of
osteoclasts through its action as a decoy receptor that blocks RANKL and RANK juxtacrine
interaction.Antibodies to RANKL can also block this interaction. Estrogen and SERMs may inhibit
the activity of osteoclasts but also promote apoptosis of osteoclasts, thus reducing their active
lifespan. Bisphosphonates also promote osteoclast apoptosis. Chemically modified tetracylines
reduce the protease degradation of the organic matrix, and anti-integrins block the initial osteoclast
adhesion to the matrix.
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their systemic use are well known, and recently, the
promise of avoiding adverse systemic effects has
been addressed by the use of localized application
of NSAIDs.93 Inhibition of cyclooxygenase-2 (COX-
2), a mediator of proinflammatory prostaglandin
activity, prevented alveolar bone loss in a rat model
of experimental periodontitis.94 The use of selective
COX-2 inhibitors in a wide range of conditions from
rheumatoid arthritis to cardiovascular disease and
cancer has dramatically expanded in the past few
years.92 Furthermore, interesting recent data suggest
that specifically blocking IL-1 and TNF dramatically
reduces the loss of alveolar bone in a monkey
model.95,96 The soluble antagonists utilized for these
studies consist of the extracellular portion of the type
I IL-1 receptor that acts as an IL-1 receptor antago-
nist, and a fusion protein of the extracellular domain
of the TNF receptor-2 linked to the Fc domain of
human IgG1 that acts as a TNF receptor antagonist.
Blocking agents were administered by intrapapillary
injection 3 times per week over a 6-week period with
significant reductions in radiographic alveolar bone
loss. These types of strategies may provide future
therapeutic modalities to treat periodontal bone
resorption, but many more studies will be required.
Bisphosphonates
Bisphosphonates are preferentially taken up by bone
tissue in relatively high concentrations and inhibit
osteoclast formation and function.12 The accumula-
tion of high levels of bisphosphonates in the bone
could potentially make them available to the sur-
rounding tissue. Bisphosphonates have proved to be
very powerful inhibitors of bone resorption when
assessed under a variety of conditions, both in cul-
ture and in vivo.97-99 It is thought that bisphospho-
nates bind to the bone surface and act directly on
osteoclasts to inhibit their resorptive activity and to
promote their apoptosis. In addition, there is evidence
to suggest that bisphosphonates also affect protein
production in osteoblasts.97 Previous findings have
identified a potential role for bisphosphonates by
inhibiting periodontal disease in animal models or
altering MMP production from human periodontal lig-
ament cells.98,99 Furthermore, bisphosphonate-com-
plexed implants result in better osteoconduction and
repair in animal models, suggesting that the inhibi-
tion of bone resorption facilitates bony healing.100
The inhibitory effect of bisphosphonates on the activ-
ity of both MMP-1 and MMP-3 have been shown in
cultured periodontal ligament cells.99 It is suggested
that these compounds possibly affect matrix metal-
loproteinases released from resident cells in the peri-
odontal attachment apparatus, including periodontal
ligament. The inhibition of MMP activity at the bone
surface may block an initiating step in the bone
resorption process.
Several studies using animal models have evalu-
ated the effects of bisphosphonates on the peri-
odontium. In naturally occurring periodontitis in dogs,
bisphosphonates had no effect in preventing peri-
odontal attachment loss, but the bisphosphonate-
treated group was found to have increased bone
above the placebo control.98 In ligature-induced peri-
odontitis in monkeys, bisphosphonate treatment
reduced the amount of attachment loss and prevented
loss of bone density.101,102 In other animal studies,
bisphosphonates had little or no effect on preventing
attachment loss and only a modest effect on the den-
sity of alveolar bone.103 In a pilot clinical trial, the effi-
cacy of the bisphosphonate drug alendronate in slow-
ing alveolar bone loss due to periodontitis was
investigated.104 Over a 9-month period, alendronate
reduced the risk of progressive alveolar bone loss.
More recently, short-term results indicated a protec-
tive effect of the bisphosphonate alendronate in peri-
odontal patients with type 2 diabetes.105 The use of
bisphosphonates to prevent and/or treat periodonti-
tis must be considered very carefully at this time.
Chemically Modified or Low-Dose Tetracyclines
Tetracyclines, broad-spectrum antibiotics, are used
extensively in the management of periodontal dis-
ease because of their ability to inhibit bacterial pro-
tein synthesis. However, newer applications of tetra-
cyclines have focused on the ability of these agents
to block tissue-destructive enzymes, such as the
matrix metalloproteinases.76,106 A group of tetracy-
clines including chlortetracycline, oxytetracycline,
demeclocycline, methacycline, doxycycline, and
minocycline chelate the cations of metalloproteinases
that are required for action. Other non-microbial
mechanisms attributed to tetracyclines include inac-
tivation of enzymes that activate metalloproteinases,
scavenging reactive oxygen species, blockade of
secretion of lysosomal proteinases, and modulation of
osteoclast functions, including the induction of osteo-
clast apoptosis.107 The mechanism by which tetra-
cyclines inhibit matrix metalloproteinases appears to
be independent of their antibacterial activity. In a vari-
ety of studies, low-dose tetracyclines have been shown
to reduce collagenase activity in gingival tissue
extracts and gingival crevicular fluid.106,109 In a clin-
ical study, neither placebo nor low-dose tetracycline
McCauley, Nohutcu 1385
S1010_IPC_AAP_553172  11/8/02  10:52 AM  Page 1385
Volume 73 • Number 11
State of the Art Review
treatment resulted in significant differences in attach-
ment level compared to baseline values.108 This study
found that patients receiving low-dose doxycycline
exibited a small gain in attachment levels, whereas
the placebo group experienced a small loss in attach-
ment. Because of the undesirable effects of long-term
tetracycline therapy, chemically modified tetracyclines
were developed to eliminate the antimicrobial prop-
erties while maintaining activities on matrix metallo-
proteinases. This modification produces a molecule
that has no antimicrobial activity but inhibits colla-
genase activity and reduces tissue breakdown.109
Currently, chemically modified tetracyclines appear to
have promising therapeutic potential in the treatment
of periodontitis.
Estrogens and Selective Estrogen Receptor
Modulators (SERMs)
Estrogen deficiency leads to accelerated bone resorp-
tion characteristic of postmenopausal osteoporosis.
Estrogen withdrawal is associated with large increases
in bone resorption, with increased osteoclast num-
bers due to enhanced osteoclast formation and activ-
ity and reduced osteoclast apoptosis. Estrogen
replacement therapy has long been considered the
first line therapy for preventing osteoporosis in
women. Treatment with estrogens clearly inhibits bone
loss as well as bone turnover and increases bone
mineral density.12 There is substantial evidence that
estrogen inhibits both osteoclast activity and differ-
entiation by regulating production of stimulatory and
inhibitory cytokines by osteoblasts and mono-
cytes.110,111 The molecular mechanism of action of
estrogens on bone, as well as other tissues, is not
fully understood. The discovery of the agents able to
exert full or partial estrogen effects on various tis-
sues led to the development of a new class of drugs
known as selective estrogen receptor modulators
(SERMs).12 The mechanism by which SERMs inhibit
bone resorption is likely to be the same as estrogen’s
mechanism, by blocking production of cytokines that
promote osteoclast differentiation and by promoting
osteoclast apoptosis.
It has been speculated that estrogen deficiency and
osteopenia/osteoporosis play a role in the progres-
sion of oral bone loss following menopause. Various
reports also have linked estrogen deficiency and
osteoporosis to increased oral bone resorption, attach-
ment loss, and tooth loss.112 It also has been demon-
strated that in estrogen-deficient postmenopausal
women, there is increased loss of interproximal alve-
olar bone height compared to estrogen-sufficient
patients over a 1-year period. Reinhardt et al. found
lower IL-1β levels in GCF of estrogen-sufficient early
postmenopausal females with periodontitis as com-
pared to estrogen-deficient patients.113 In another
study, the same group reported that estrogen sup-
plementation was associated with reduced gingival
inflammation and reduced frequency of clinical
attachment loss in osteopenic/osteoporotic women
in early menopause.114 Van Steenberghe et al. com-
pared lumbar spine bone mineral density with man-
dibular bone mass assessed by standardized intra-
oral radiographs.115 A significant but moderate
correlation was observed during the 5-year period.
In contrast, Nordyred, in a cross-sectional study,
reported no difference in clinical attachment level or
alveolar bone loss.116 Estrogen replacement therapy
was reported to be associated with less gingival bleed-
ing after correction for age. However, data in the peri-
odontal literature indicate that estrogen supplemen-
tation may reduce the rate of clinical attachment loss
in osteopenic/osteoporotic women.114
Osteoprotegerin (OPG)
There are a few studies in the literature relating OPG
and its potential role in periodontal tissues. Shiba et
al. investigated the expression of OPG levels in PDL
cells and observed no age-related changes in the
expression of OPG, although OPG mRNA levels were
expected to decrease.117 Wada et al. reported that
conditioned medium from human periodontal liga-
ment cells contained OPG and that periodontal liga-
ment cells synthesized enough bioactive OPG to
inhibit osteoclastic differentiation and function.118 In
a recent landmark study, Teng et al. investigated the
role of RANKL in alveolar bone destruction during
periodontal infection using an animal model.26 Micro-
bial stimulation by A. actinomycetemcomitans induced
RANKL expression on the surface of CD4+ cells, and
in vivo inhibition of RANKL function with the decoy
receptor OPG diminished alveolar bone destruction
and reduced the number of periodontal osteoclasts
after microbial challenge. These results indicate that
the alveolar bone destruction observed in periodon-
titis is due, at least in part, to the action of osteoclasts
and is mediated by RANKL. In other words, A. actin-
omycetemcomitans activates CD4+ T cells in the peri-
odontium and induces them to express RANKL, the
key mediator of alveolar bone destruction in microor-
ganism-induced infection. Thus, inhibition of the func-
tion of RANKL may have therapeutic value to prevent
or interrupt alveolar bone and/or tooth loss in
humans.
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FUTURE STRATEGIES
The periodontal therapist has a challenge treating
bone loss due to periodontal disease. When consid-
ering different therapeutics, one needs to keep the
goal in view of the presenting periodontal status.
Inhibitors of resorption are most effective when
administered prior to the time when a patient would
be susceptible to bone loss, i.e., as a preventive mea-
sure. Since we are as yet unable to accurately pre-
dict these periods, we are continually challenged with
the decision of appropriate therapeutics. Preventing
bone loss in a patient who will not likely experience
bone loss has little value. Preventing further bone
loss in a patient who has already experienced bone
loss is obviously not as valuable as preventing the
initial bone loss, but is still a worthy goal. Patients
who have already experienced bone loss may be
best suited to a regenerative procedure followed by
a preventive strategy to reduce their chances of
recurrent bone loss. All of these scenarios would
benefit from a better understanding of prognostic
features of our patients’ susceptibility to bone loss.
Improved understanding of prognosis will likely arise
through better molecular identification of disease
susceptibility genes. In the meantime, much can still
be learned regarding the preventive strategies to
abate bone resorption. Rodan and Martin provide
compelling discussion of new targets of pharmaco-
logic modulation of osteoclast formation and activ-
ity that may be applicable to the treatment of peri-
odontal disease.12 Blocking the action of RANKL
through the use of OPG was discussed above, but
other strategies such as the use of antibodies to
RANKL are being explored with promise. Blocking
the adhesion of osteoclasts to their target matrix
through the use of agents that disrupt integrins has
been reported to inhibit bone resorption and may
provide viable options after clinical investigation.119
The utilization of anti-inflammatory agents such as
antagonists to IL-1 and TNF-α also must be consid-
ered since results from animal studies suggest they
may also show promise in humans.95 Recently,
strategies other than tetracyclines for inhibiting MMPs
have been described in animal models.120 Peptides
that specifically inhibit MMPs reduce MMP activity
and bone loss and may have therapeutic benefit with
further study.
We need to continue seeking viable antiresorptives
while, at the same time, striving to better identify
patients who are appropriate candidates for these
types of therapeutics. As these 2 goals converge, we
will be in a much better position to effectively inter-
vene in the osseous destruction associated with peri-
odontal diseases.
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